← Russell 3000 cross-section

CBLL Ceribell, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$913m
Revenue TTM
$102m
Net income TTM
$-66m
Free cash flow
$-55m
Composite score
Sector rank
#2064

Valuation

P / E
EV / EBITDA
EV / sales
7.7
FCF yield
-5.99%
Earnings yield vs 10-yr
-11.96pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-64.7%
EBITDA margin
-67.5%
ROE
-51.4%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-8.74m
Buyers
0
Sellers
8

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenue fluctuates primarily based on the number of active accounts and the volume of Wearable usage. We expect that our revenue will continue to fluctuate quarter-to-quarter due to a variety of factors, including the potential success of our sales force in extending adoption of the Ceribell System to new accounts and expanding the utilization of the Ceribell System in existing accounts. For purposes of managing our business, we do not separately track increases in revenue solely attributable to new accounts. …Ceribell, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →